View Item 

Show simple item record

Examining the relationship of immunotherapy and wound complications following flap reconstruction in patients with head and neck cancer
dc.contributor.authorMays, Ashley C.
dc.contributor.authorYarlagadda, Bharat
dc.contributor.authorAchim, Virginie
dc.contributor.authorJackson, Ryan
dc.contributor.authorPipkorn, Patrik
dc.contributor.authorHuang, Andrew T.
dc.contributor.authorRajasekaran, Karthik
dc.contributor.authorSridharan, Shaum
dc.contributor.authorRosko, Andrew J.
dc.contributor.authorOrosco, Ryan K.
dc.contributor.authorCoughlin, Andrew M.
dc.contributor.authorWax, Mark K.
dc.contributor.authorShnayder, Yelizaveta
dc.contributor.authorSpanos, William C.
dc.contributor.authorFarwell, Donald Gregory
dc.contributor.authorMcDaniel, Lee S.
dc.contributor.authorHanasono, Matthew M.
dc.date.accessioned2021-05-12T17:26:13Z
dc.date.available2022-06-12 13:26:12en
dc.date.available2021-05-12T17:26:13Z
dc.date.issued2021-05
dc.identifier.citationMays, Ashley C.; Yarlagadda, Bharat; Achim, Virginie; Jackson, Ryan; Pipkorn, Patrik; Huang, Andrew T.; Rajasekaran, Karthik; Sridharan, Shaum; Rosko, Andrew J.; Orosco, Ryan K.; Coughlin, Andrew M.; Wax, Mark K.; Shnayder, Yelizaveta; Spanos, William C.; Farwell, Donald Gregory; McDaniel, Lee S.; Hanasono, Matthew M. (2021). "Examining the relationship of immunotherapy and wound complications following flap reconstruction in patients with head and neck cancer." Head & Neck 43(5): 1509-1520.
dc.identifier.issn1043-3074
dc.identifier.issn1097-0347
dc.identifier.urihttps://hdl.handle.net/2027.42/167524
dc.description.abstractBackgroundImmunotherapy agents are used to treat advanced head and neck lesions. We aim to elucidate relationship between immunotherapy and surgical wound complications.MethodsRetrospective multi‐institutional case series evaluating patients undergoing ablative and flap reconstructive surgery and immunotherapy treatment. Main outcome: wound complications.ResultsEight‐two (62%) patients received preoperative therapy, 89 (67%) postoperative, and 33 (25%) in both settings. Forty‐one (31%) patients had recipient site complications, 12 (9%) had donor site. Nineteen (14%) had major recipient site complications, 22 (17%) had minor. There was no statistically significant difference in complications based on patient or tumor‐specific variables. Preoperative therapy alone demonstrated increased major complications (odds ratio [OR] 3.7, p = 0.04), and trend to more donor site complications (OR 7.4, p = 0.06), however treatment in both preoperative and postoperative therapy was not.ConclusionsPreoperative immunotherapy may be associated with increased wound complications. Controlled studies are necessary to delineate this association and potential risks of therapy.
dc.publisherJohn Wiley & Sons, Inc.
dc.subject.otherimmunotherapy
dc.subject.otherfree flap reconstruction
dc.subject.otherhead and neck cancer
dc.subject.otherwound complications
dc.titleExamining the relationship of immunotherapy and wound complications following flap reconstruction in patients with head and neck cancer
dc.typeArticle
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelOtolaryngology
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/167524/1/hed26601_am.pdf
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/167524/2/hed26601.pdf
dc.identifier.doi10.1002/hed.26601
dc.identifier.sourceHead & Neck
dc.identifier.citedreferenceHanasono M, Zevallos JP, Skoracki RJ, Yu P. A prospective analysis of bony versus soft‐tissue reconstruction for posterior mandibular defects. Plast Reconstr Surg. 2010; 125 ( 5 ): 1413 ‐ 1421.
dc.identifier.citedreferencePasquali S, Hadjinicolaou AV, Chiarion Sileni V, Rossi CR, Mocellin S. Systemic treatments for metastatic cutaneous melanoma. Cochrane Database Syst Rev. 2018; 2: CD011123.
dc.identifier.citedreferencePuza CJ, Bressler ES, Terando AM, et al. The emerging role of surgery for patients with advanced melanoma treated with immunotherapy. J Surg Res. 2019; 236: 209 ‐ 215.
dc.identifier.citedreferenceBello DM, Panageas KS, Hollmann T, et al. Survival outcomes after metastasectomy in melanoma patients categorized by response to checkpoint blockade. Ann Surg Oncol. 2020; 27 ( 4 ): 1180 ‐ 1188.
dc.identifier.citedreferenceSun J, Kirichenko DA, Chung JL, et al. Perioperative outcomes of melanoma patients undergoing surgery after receiving immunotherapy or targeted therapy. World J Surg. 2020; 44 ( 4 ): 1283 ‐ 1293.
dc.identifier.citedreferenceElias AW, Kasi PM, Stauffer JA, et al. The feasibility and safety of surgery in patients receiving immune checkpoint inhibitors: a retrospective study. Front Oncol. 2017; 7: 121.
dc.identifier.citedreferenceTopalian SL, Bhatia S, Amin A, et al. Neoadjuvant nivolumab for patients with resectable Merkel cell carcinoma in the CheckMate 358 trial. J Clin Oncol. 2020; 38 ( 22 ): 2476 ‐ 2487. https://doi.org/10.1200/JCO.20.00201.
dc.identifier.citedreferenceBakos O, Lawson C, Rouleau S, Tai LH. Combining surgery and immunotherapy: turning an immunosuppressive effect into a therapeutic opportunity. J Immunother Cancer. 2018; 6 ( 1 ): 86.
dc.identifier.citedreferenceHanna GJ, Adkins DR, Zolkind P, Uppaluri R. Rationale for neoadjuvant immunotherapy in head and neck squamous cell carcinoma. Oral Oncol. 2017; 73: 65 ‐ 69.
dc.identifier.citedreferenceUppaluri R, Winkler AE, Lin T, et al. Biomarker and tumor responses of oral cavity squamous cell carcinoma to trametinib: a phase II neoadjuvant window‐of‐opportunity clinical trial. Clin Cancer Res. 2017; 23 ( 9 ): 2186 ‐ 2194.
dc.identifier.citedreferenceSchoenfeld JD, Hanna GJ, Jo V, et al. Neoadjuvant nivolumab +/− ipilimumab in patients with oral cavity cancer. Oral presentation at: 2020 Multidisciplinary Head and Neck Cancers Symposium; February, 2020; Scottsdale, AZ
dc.identifier.citedreferencePires da Silva I, Glitza IC, Haydu LE, et al. Incidence, features and management of radionecrosis in melanoma patients treated with cerebral radiotherapy and anti‐PD‐1 antibodies. Pigment Cell Melanoma Res. 2019; 32 ( 4 ): 553 ‐ 563.
dc.identifier.citedreferenceGoyal N, Yarlagadda BB, Deschler DG, et al. Surgical site infections in major head and neck surgeries involving pedicled flap reconstruction. Ann Otol Rhinol Laryngol. 2017; 126 ( 1 ): 20 ‐ 208.
dc.identifier.citedreferenceYarlagadda BB, Deschler DG, Rich DL, et al. Head and neck free flap surgical site infections in the era of the surgical care improvement project. Head Neck. 2016; 38 ( Suppl 1 ): E392 ‐ E398.
dc.identifier.citedreferenceSuh JD, Sercarz JA, Abemayor E, et al. Analysis of outcome and complications in 400 cases of microvascular head and neck reconstruction. Arch Otolaryngol Head Neck Surg. 2004; 130 ( 8 ): 962 ‐ 966.
dc.identifier.citedreferenceLee EI, Chao AH, Skoracki RJ, Yu P, DeMonte F, Hanasono MM. Outcomes of calvarial reconstruction in cancer patients. Plast Reconstr Surg. 2014; 133: 675 ‐ 682.
dc.identifier.citedreferenceChao AH, Yu P, Skoracki R, DeMonte F, Hanasono M. Microsurgical reconstruction of composite scalp and calvarial defects in patients with cancer: a 10‐year experience. Head Neck. 2012; 34 ( 12 ): 1759 ‐ 1164.
dc.identifier.citedreferenceHanasono M, Silva AK, Yu P, Skoracki RJ. A comprehensive algorithm for oncologic maxillary reconstruction. Plast Reconstr Surg. 2013; 131 ( 1 ): 47 ‐ 60.
dc.identifier.citedreferenceChang EI, Yu P, Skoracki RJ, Liu J, Hanasono MM. Comprehensive analysis of functional outcomes and survival after microvascular reconstruction of glossectomy defects. Ann Surg Oncol. 2015; 22: 3061 ‐ 3069.
dc.identifier.citedreferenceEngel H, Huang JJ, Lin CY, et al. A strategic approach for tongue reconstruction to achieve predictable and improved functional and aesthetic outcomes. Plast Reconstr Surg. 2010; 126 ( 6 ): 1967 ‐ 1977.
dc.identifier.citedreferenceZafareo M, Weber R, Lewin J, Roberts D, Hanasono M. Complications and functional outcomes following complex oropharyngeal reconstruction. Head Neck. 2010; 32 ( 8 ): 1003 ‐ 1011.
dc.identifier.citedreferenceMicrovascular Committee of the American Academy of Otolaryngology – Head & Neck Surgery. Salvage laryngectomy and laryngopharyngectomy: multicenter review of outcomes associated with a reconstructive approach. Head Neck. 2019; 41 ( 1 ): 16 ‐ 29.
dc.identifier.citedreferenceHanasono M, Sacks J, Goel N, Ayad M, Skoracki R. The anterolateral thigh free flap for skull base reconstruction. Otolaryngol Head Neck Surg. 2009; 140: 855 ‐ 860.
dc.identifier.citedreferenceHanasono M, Silva A, Skoracki R, et al. Skull base reconstruction: an updated approach. Plast Reconstr Surg. 2011; 128 ( 3 ): 675 ‐ 686.
dc.identifier.citedreferenceHanasono M, Silva A, Yu P, et al. Comprehensive management of temporal bone defects after oncologic resection. Laryngoscope. 2012; 122 ( 12 ): 2663 ‐ 2669.
dc.identifier.citedreferenceEmerick KS, Deschler DG. Incidence of donor site skin graft loss requiring surgical intervention with the radial forearm free flap. Head Neck. 2007; 29: 573 ‐ 576.
dc.identifier.citedreferenceHekner DD, Abbink JH, van Es RJ, Rosenberg A, Koole R, van Cann EM. Donor‐site morbidity of the radial forearm free flap versus the ulnar forearm free flap. Plast Reconstr Surg. 2013; 132: 387 ‐ 393.
dc.identifier.citedreferenceLutz BS, Wei FC, Chang SC, Yang KH, Chen IH. Donor site morbidity after suprafascial elevation of the radial forearm flap: a prospective study in 95 consecutive cases. Plast Reconstr Surg. 1999; 103 ( 1 ): 132 ‐ 137.
dc.identifier.citedreferenceMomoh AO, Yu P, Skoracki RJ, Liu S, Feng L, Hanasono MM. A prospective cohort study of fibula free flap donor‐site morbidity in 157 consecutive patients. Plast Reconstr Surg. 2011; 128: 714 ‐ 720.
dc.identifier.citedreferenceHanasono MM, Skoracki RJ, Yu P. A prospective study of donor‐site morbidity after anterolateral thigh fasciocutaneous and myocutaneous free flap harvest in 220 patients. Plast Reconstr Surg. 2010; 125: 209 ‐ 214.
dc.identifier.citedreferenceLipa JE, Butler CE. Enhancing the outcome of free latissimus dorsi muscle flap reconstruction of scalp defects. Head Neck. 2004; 26 ( 1 ): 46 ‐ 53.
dc.identifier.citedreferenceLin CH, Wei FC, Levin LS, Chen MC. Donor‐site morbidity comparison between endoscopically assisted and traditional harvest of free latissimus dorsi muscle flap. Plast Reconstr Surg. 1999; 104 ( 4 ): 1070 ‐ 1077; quiz 1078.
dc.identifier.citedreferenceWeinrach J, Cronin E, Smith B, et al. Preventing seroma in the latissimus dorsi flap donor site with fibrin sealant. Ann Plast Surg. 2004; 53 ( 1 ): 12 ‐ 16.
dc.identifier.citedreferenceHeo JW, Park SO, Jin US. Donor‐site morbidities in 615 patients after breast reconstruction using a free muscle‐sparing type I transverse rectus abdominis myocutaneous flap: a single surgeon experience. J Plast Surg Hand Surg. 2018; 52 ( 6 ): 325 ‐ 332.
dc.identifier.citedreferenceFischer S, Klinkenberg M, Behr B, et al. Comparison of donor‐site morbidity and satisfaction between anterolateral thigh and parascapular free flaps in the same patient. J Reconstr Microsurg. 2013; 29: 537 ‐ 544.
dc.identifier.citedreferenceFerrari S, Ferri A, Bianchi B, Varazzani A, Perlangeli G, Sesenna E. Donor site morbidity after scapular tip free flaps in head‐and‐neck reconstruction. Microsurgery. 2015; 35 ( 6 ): 447 ‐ 450.
dc.identifier.citedreferenceDobosz P, Dzieciatkowski T. The intriguing history of cancer immunotherapy. Front Immunol. 2019; 10: 2965.
dc.identifier.citedreferenceSaleh K, Eid R, Haddad FG, Khalife‐Saleh N, Kourie HR. New developments in the management of head and neck cancer—Impact of pembrolizumab. Ther Clin Risk Manag. 2018; 14: 295 ‐ 303.
dc.identifier.citedreferenceAhn JW, Shalabi D, Correa‐Selm LM, Dasgeb B, Nikbakht N, Cha J. Impaired wound healing secondary to bevacizumab. Int Wound J. 2019; 16 ( 4 ): 1009 ‐ 1012.
dc.identifier.citedreferenceBarami K, Fernandes R. Incidence, risk factors and management of delayed wound dehiscence after craniotomy for tumor resection. J Clin Neurosci. 2012; 19 ( 6 ): 854 ‐ 857.
dc.identifier.citedreferenceHwang V, Mendez E, Chow LQM, et al. Wound complications in head and neck squamous cell carcinomas after anti‐PD‐1 therapy. Laryngoscope. 2019; 129 ( 12 ): E428 ‐ E433.
dc.identifier.citedreferenceR Core Team. R: A Language and Environment for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing; ( 2019 ). https://www.R-project.org/. Accessed September 30, 2019.
dc.identifier.citedreferenceFerris RL, Blumenschein G, Fayette J, et al. Nivolumab for recurrent squamous‐cell carcinoma of the head and neck. N Engl J Med. 2016; 375 ( 19 ): 1856 ‐ 1867.
dc.identifier.citedreferenceFerris RL, Blumenschein G, Fayette J, et al. Nivolumab vs investigator’s choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2‐year long‐term survival update of CheckMate 141 with analyses by tumor PD‐L1 expression. Oral Oncol. 2018; 81: 45 ‐ 51.
dc.working.doiNOen
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
hed26601_am.pdf
Size:
240.5KB
Format:
PDF
View/Open
Name:
hed26601.pdf
Size:
806.5KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.